US Patent

US8063043 — Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4â²-(trifluoromethoxy)[1,1â²-biphenyl]-3-carboxamide

Composition of Matter · Assigned to Novartis AG · Expires 2029-09-15 · 3y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects salts of the compound N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4â²-(trifluoromethoxy)[1,1â²-biphenyl]-3-carboxamide.

USPTO Abstract

Salts of N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4â²-(trifluoromethoxy)[1,1â²-biphenyl]-3-carboxamide are prepared and characterized.

Drugs covered by this patent

sonidegib-phosphate (SONIDEGIB PHOSPHATE)

Patent Metadata

Patent number: US8063043
Jurisdiction: US
Classification: Composition of Matter
Expires: 2029-09-15
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.